Profilaktika tromboticheskikh oslozhneniy s pomoshch'yu Fragmina u onkologicheskikh bol'nykh, poluchavshikh khimioterapiyu


Cite item

Full Text

Abstract

Изучено влияние низкомолекулярного гепарина далтепарина натрия (Фрагмин) на систему гемостаза и частоту тромботических осложнений у 180 онкологических больных, получавших химиотерапию. Показано, что применение Фрагмина на фоне химиотерапии снижает интенсивность внутрисосудистого свертывания крови и частоту тромботических осложнений.

About the authors

O V Somonova

ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

A V Madzhuga

ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

A L Elizarova

ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

G N Zubrikhina

ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

References

  1. Prandoni P, Lensing A, Cogo A et al. The long - term clinical course of acute deep vein thrombosis. Ann Intern Med 1996: 125: 1–7.
  2. Smorenburg S.M., Hutten B.A., Prins M.N. Should patients with venous thromboembolism and cancer be treated differently? Haemostasis 1999; 29 (suppl): 91–7.
  3. Levine M.N., Lee A.Y., Kakkar A.K. Thrombosis and cancer. American Society of Clinical Oncology, 41 Annual Meeting 2005; 13–17: 748–77.
  4. Arcelus J.I. Recognizing the risk of VTE in surgical patients. International. Surgical Thrombosis Meeting «Optimizing VTE Management in surgical patients» (abstract). Greece, 2007.
  5. Bromberg M.E., Cappello M. Cancer and blood coagulation: molecular aspects. Cancer 1999; 3: 132–8.
  6. Schmitt M, Kuhn W, Hardee N, Grief H. Thrombophilic state in breast cancer. Seminars in double - blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparin in the prevention of venous thromboembolism after high risk abdominal surgery: the PEGASUS Study (abstract). Blood 2003; 102: 15a.
  7. Weitz J.C., Israel V.K., Waisman J.R. et al. Chemotherapy – induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. J Thromb Haemost 2002; 88 (2): 213–20.
  8. Levine M.N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thrombos Haemostas 1997; 78: 133–6.
  9. Kakkar A.K., Williamson R.C.N. Prevention of venous thromboembolism in cancer patients. Seminars in Thrombosis and Haemostasis; 1999: 25 (2): 239–43.
  10. Kakkar A.K., Haas S, Walsh D et al. Compliance with recommended prophylxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. J Thromb Haemost 2004; 2: 221–7.

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies